S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study

OBJECTIVE: The SOFT study previously demonstrated that S-1 and oxaliplatin (SOX) plus bevacizumab was non-inferior to l-leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) plus bevacizumab in terms of the primary end point of progression-free survival (PFS) as first-line chemotherapy for metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Baba, Hideo, Yamada, Yasuhide, Takahari, Daisuke, Matsumoto, Hiroshi, Yoshida, Kazuhiro, Nakamura, Masato, Yoshida, Motoki, Iwamoto, Shigeyoshi, Shimada, Ken, Komatsu, Yoshito, Sasaki, Yasutsuna, Satoh, Taroh, Takahashi, Keiichi, Mishima, Hideyuki, Muro, Kei, Watanabe, Masahiko, Sakata, Yuh, Morita, Satoshi, Shimada, Yasuhiro, Sugihara, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ESMO Open 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519807/
https://www.ncbi.nlm.nih.gov/pubmed/28761727
http://dx.doi.org/10.1136/esmoopen-2016-000135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519807/
https://www.ncbi.nlm.nih.gov/pubmed/28761727
http://dx.doi.org/10.1136/esmoopen-2016-000135

Ejemplares similares